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Abstract
Clozapine is a particularly effective antipsychotic medication but its use is curtailed by the risk of
clozapine-induced agranulocytosis/granulocytopenia (CIAG), a severe adverse drug reaction
occurring in up to 1% of treated individuals. Identifying genetic risk factors for CIAG could
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enable safer and more widespread use of clozapine. Here we perform the largest and most
comprehensive genetic study of CIAG to date by interrogating 163 cases using genome-wide
genotyping and whole-exome sequencing. We find that two loci in the major histocompatibility
complex are independently associated with CIAG: a single amino acid in HLA-DQB1 (126Q)
(P=4.7×10−14, odds ratio, OR=0.19, 95% CI 0.12–0.29) and an amino acid change in the
extracellular binding pocket of HLA-B (158T) (P=6.4×10−10, OR=3.3, 95% CI 2.3–4.9). These
associations dovetail with the roles of these genes in immunogenetic phenotypes and adverse drug
responses for other medications, and provide insight into the pathophysiology of CIAG.

Introduction

Author Manuscript

Clozapine-induced agranulocytosis/granulocytopenia (CIAG) is a rare adverse drug event
that occurs in 1% of treated individuals and can be fatal if not detected early1. As a result,
clozapine is underused despite its superior efficacy and particular utility in treatmentresistant schizophrenia2. Our goal is to identify genetic risk factors for CIAG that could
enable safer and increased use of clozapine.
Because of the specific nature of this adverse drug response and the role of the major
histocompatibility complex (MHC) in adverse drug responses, candidate gene studies have
focused on human leukocyte antigen (HLA) alleles in CIAG.3, 4, 5, 6, 7, 8 A small exome
sequencing study of CIAG was unrevealing9. While nominally significant HLA associations
have been reported, no study to our knowledge has reported unequivocal statistical
significance or the dissection of the complex linkage disequilibrium (LD) relationships in
the MHC.

Author Manuscript

Using multiple ascertainment schemes, we assemble the largest CIAG cohort to date (163
cases, 54.0% never previously reported, Supplementary Table 1). We conduct a genome
survey using whole-exome sequencing and genome-wide genotyping to test for association
with CIAG (Figure 1, Supplementary Table 2). We show CIAG is associated with two
independent amino acid changes in HLA-B (158T) and HLA-DQB1 (126Q). However, the
odds ratios for these risk factors do not suggest immediate clinical application in predictive
testing.

Results
Genome-wide common variant association study

Author Manuscript

We performed a genome-wide association study of 8,809,853 genotyped and imputed
common variants in 161 CIAG cases (2 additional cases had exome sequencing or exome
array data) and 1,196 controls of European ancestry. After controlling for ancestry
(Supplementary Fig. 1), no loci exceeded genome-wide significance (P < 5×10−8, Figure 2).
Our sample size was powered to detect common genetic variants with effect sizes of clinical
utility (e.g., power was >99% for an odds ratio > 4 and MAF > 10%) (Supplementary Fig.
2). The SNP with the best evidence for association was in an intron in HLA-B (rs41549217,
P=2.07×10−7, OR=4.66, 95% CI 2.6–8.3, Supplementary Data 1). We specifically examined
the distribution of p-values of SNPs previously shown to be associated with immune-
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mediated diseases, but did not detect any enrichment (Supplementary Fig. 3). Evaluation of
copy number variation did not reveal any associations with CIAG. No protein encoded by a
gene implicated by GWAS is known to bind clozapine10.
Exome-wide rare variant association study
We tested protein-coding variants (MAF < 5%) for association using whole-exome
sequencing data from 67 CIAG cases and 376 untreated population controls. For variants
that were also genotyped on the exome array, we merged the sequencing data with exome
array data from 81 CIAG cases and 3,294 controls of European ancestry. We also used raw
count data from ~4,300 samples of European ancestry from the NHLBI Exome Sequencing
Project as an additional control reference to increase statistical power11. The top finding is a
low frequency missense variant in BTNL2 annotated as benign by PolyPhen-2 (rs28362679,
P=4.14×10−7, OR=3.9, 95% CI 1.2–12.9, Supplementary Data 2).

Author Manuscript
Author Manuscript

Next, we used a burden test to evaluate whether cases were more likely to be carriers of a
functional variant in a gene compared to controls in the exome sequencing data. We divided
rare variants into different functional categories and MAF ranges and found that BTNL2
(P=7.0×10−8) was the only gene to exceed a conservative significance threshold of
P=2.5×10−6, corresponding to a Bonferroni correction of 20,000 genes tested12 (Figure 3).
None of the protein products of these genes is known to bind clozapine10. The BTNL2 signal
is driven by two independent variants: the top SNP noted above (rs28362679) and a
conditionally independent missense variant annotated as benign by PolyPhen-2
(rs143211074; P=6.0×10−6, OR=4.4, 95% CI 1.10–17.8). These associations replicated
using the exome array and NHLBI Exome Sequencing Project data (Supplementary Fig. 4).
BTNL2 is in the MHC region and is in strong LD with HLA-DQB1 and HLA-DRB1, which
have been associated with autoimmune diseases and adverse drug reactions including
CIAG7, 13. BTNL2 codes for the butyrophilin-like protein 2, a member of the
immunoglobulin gene superfamily with a role in regulating T-cell activation14. Given its
location in a region of very high LD, the BTNL2 association could implicate it directly or
reflect indirect associations with classical HLA alleles.
Classical HLA allele imputation

Author Manuscript

We imputed four-digit classical HLA alleles and amino acid sequences in 162 CIAG cases
and 4,319 controls of European ancestry15 from a reference panel of 5,225 individuals using
SNP2HLA15. The cases, mainly of northwestern European and Ashkenazi Jewish ancestry,
were well-matched to controls (Supplementary Fig. 5). Two independent loci are associated
with CIAG after multiple-testing correction (Figure 4). The top signal is an amino acid
change in HLA-DQB1 (126Q) that is in strong LD with HLA-DQB1*05:02 (P=4.7×10−14,
OR=0.19, 95% CI 0.12–0.29). After conditioning on HLA-DQB1 126Q, a genome-wide
significant signal in HLA-B remains (threonine to alanine at residue 158, Pcond =1.54×10−8,
OR=3.11, 95% CI 2.1–4.6). No other statistically significant loci remain after conditioning
on both HLA-DQB1 126Q and HLA-B 158T (Supplementary Data 3).
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To determine whether the BTNL2 signal is independent of the HLA-B 158T and HLA-DQB1
126Q signals, we analyzed samples with imputed HLA alleles and genotyped BTNL2
variants (146 CIAG cases and 3,364 controls). In conditional analyses, we observed that the
most associated BTNL2 variant (rs28362679) was in high LD with HLA-DQB1 126Q
(R2=0.618) and the other BTNL2 variant (rs143211074) had a low correlation with HLA-B
158T (R2=0.042) (Supplementary Fig. 6). To determine whether the association in the
region was better explained by the two variants in BTNL2 or the two HLA-alleles, we
compared the likelihoods of models with HLA-DQB1 126Q and HLA-B 158T predicting
CIAG compared to a model with the two BTNL2 variants. The combination of HLA-DQB1
126Q and HLA-B 158T is 27,000 times more likely to explain the MHC association with
CIAG than the two BTNL2 variants. We also looked at whether a model including one or
both BTNL2 variants in addition to HLA-DQB1 126Q and HLA-B 158T explained the
association better than HLA-B and HLA-DQB1 alone. We found including rs143211074 in
the model was 13 times more likely to explain the association than the two-component
model of HLA-B and HLA-DQB1, but there was no improvement when we added
rs28362679. These results indicate rs143211074 could be independently associated with
CIAG, but the more likely explanation is rs143211074 is tagging an HLA haplotype that is
not genome-wide significant on its own (given that rs143211074 and HLA-DRB1*04:02 are
highly correlated with R2=0.77).
HLA sequence alignment

Author Manuscript

We used the IMGT/HLA database16 (http://www.ebi.ac.uk/ipd/imgt/hla) to determine which
classical alleles correspond to HLA-DQB1 126Q and HLA-B 158T and to align these results
with previous candidate gene studies of CIAG. Since having a glutamine at position 126 in
HLA-DQB1 is protective for CIAG, the most common high-risk allele is HLA-DQB1*05:02
which has a histidine at position 126. This is consistent with prior reports of an association
of CIAG with HLA-DQB1 6672G>C (a variant in strong LD with HLA-DQB1*05:02)4, 5.
HLA-B*38, HLA-B*39, and HLA-B*67 are the most common alleles with a threonine at
position 158 in the protein sequence (consistent with previous reports although none met
contemporary significance levels)3, 4, 8. Our results cannot differentiate whether the amino
acids we identified are causal or whether the overall configuration of these genetically
related isoforms confers risk for CIAG.
CIAG severity by HLA-B and HLA-DQB1 carrier status

Author Manuscript

Finally, we tested for differences in CIAG severity (as indexed by minimum absolute
neutrophil count, ANC) according to risk allele status of HLA-DQB1 and HLA-B among 149
cases with these data. Cases who were carriers of HLA-B 158T demonstrated significantly
lower ANC than non-carriers (P<0.01, Figure 5). However, as nearly all cases with
substantial Ashkenazi Jewish ancestry carried the HLA-B 158T allele (Supplementary Fig.
7), it is not possible to determine conclusively whether some of this signal could be driven
by an unexplored feature of ascertainment or population difference. Hence we repeated the
analysis after excluding cases with Ashkenazi Jewish ancestry (PC1>0.02) and subsequently
correcting the phenotype for ancestry and sample cohort and observed a consistent effect but
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of reduced significance (P=0.049) owing to reduced power because of the number of 158T
alleles excluded (Supplementary Fig. 8). Similar analyses of time to onset of CIAG were not
significant (data not shown).
Modeling of clozapine binding to HLA-B

Author Manuscript

The associations of HLA-DQB1 and HLA-B with CIAG are biologically plausible. HLADQB1 is part of the MHC Class II antigen-presentation pathway and has been associated
with autoimmune diseases (e.g., rheumatoid arthritis)17 and a range of immunogenetic
phenomena (e.g., allergic sensitization, human papillomavirus seropositivity, and chronic
hepatitis B infection)18, 19, 20. HLA-B is an important component of the MHC Class I
antigen-presentation pathway and a “hot spot” for serious adverse drug reactions including
flucloxacillin-induced liver injury,21 carbamazepine-induced Stevens-Johnson syndrome22,
and abacavir hypersensitivity syndrome23. For several of these adverse drug reactions, the
mechanism appears to be off-target binding of a drug molecule to the antigen-binding cleft
of the HLA-B protein23.
Similar to what has been done for abacavir23, we used a molecular docking approach to
determine that clozapine binds with relatively high affinity to the putative HLA-B*39
antigen-presenting peptide groove when there is a threonine at position 158 (Figure 6).
Docking simulations also suggested a potential for clozapine to bind in the pockets of HLAB*57:01 and HLA-B*35:08 with predicted affinities much higher than that for multiple other
HLA-B variants (Supplementary Fig. 9). As a negative control, docking studies showed that
clozapine had low binding affinities for the antigen-presenting pockets of HLA-A proteins.

Discussion
Author Manuscript
Author Manuscript

In conclusion, we identified two independent loci in the MHC region that are associated
with CIAG: HLA-DQB1 and HLA-B. These findings are consistent with previous results but
the evidence is now much stronger in this comprehensive analysis. Moreover, we localized
the signal to two amino acids (HLA-DQB1 126Q and HLA-B 158T), but cannot distinguish
whether these amino acids are causal or if the overall configuration of the alleles confers risk
for CIAG. Although these data greatly clarify the contributions of HLA variation to CIAG,
the odds ratios do not immediately suggest clinical application in screening. If we consider a
genetic test that was positive if an individual carried either risk factor, the sensitivity and
specificity of such a test would be 0.36 and 0.89. Because more than half of cases do not
carry these two relatively infrequent risk factors, a predictive test based solely on HLADQB1 and HLA-B could not define a truly “safe” group for clozapine use. We note that 7
CIAG cases (4.3%) carried two risk alleles, suggesting that this combination had particularly
high risk compared to the population expectation of 0.3–0.4%. These genetic insights could
further understanding of the biological process underlying CIAG and, as other non-genetic
and genetic risk factors for CIAG are identified, constitute an important component of tests
to screen patients for the safer use of clozapine.
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Methods
Ethical Statement
The study was approved by Institutional Review Boards at the University of North Carolina
(http://research.unc.edu/offices/human-research-ethics) and at Massachusetts General
Hospital (http://healthcare.partners.org/phsirb). Research was carried out in accordance with
the Declaration of Helsinki. Written informed consent was obtained from all participants (or
legal guardians, if applicable).
Sample Description

Author Manuscript

We formed the Clozapine-Induced Agranulocytosis Consortium (CIAC) to further this effort
by bringing together nearly all investigators in the area and to ascertain new cases. CIAG
(clozapine-induced agranulocytosis/granulocytopenia) cases developed agranulocytosis
(absolute neutrophil count, ANC < 500/mm3) or granulocytopenia (500 ≤ ANC ≤
1,000/mm3) while taking clozapine and without a known medical condition that increases
risk for agranulocytosis (e.g., hematological disorder or autoimmune disease). There were
98 cases with agranulocytosis (60.1%), 61 cases with granulocytopenia (37.4%), and 4 cases
(2.5%) included on the basis of clinical judgment due to a precipitous drop in ANC to <
1,500/mm3 while being intensively monitored. We allowed any primary psychiatric
diagnosis (although most subjects had schizophrenia or schizoaffective disorder) and any
reported ancestry was allowed. Heterogeneity due to ANC threshold, diagnosis, and ancestry
was addressed analytically.

Author Manuscript

Subjects were identified in two ways. Opportunistic ascertainment was via a broad survey of
colleagues to identify all worldwide samples in existing CIAG collections that allowed rapid
and efficient identification of existing CIAG cases and controls exposed to clozapine
without CIAG. This included cases from the International Severe Adverse Events
Consortium (iSAEC,), http://www.saeconsortium.org). Systematic assessment included
identification of additional cases from the Novartis and Teva clozapine registries (https://
www.clozarilcare.com/care, https://www.clozapineregistry.com), and the electronic
pharmaceutical record from the Pennsylvania state hospital system. Briefly, we contacted
the physician of record to confirm an episode of CIAG, the physician then obtained
permission from the potential subject to release contact information, and we then contacted
the subject to attempt recruitment into this study.

Author Manuscript

We attempted to obtain and review medical records for all subjects. Using a standardized
review form, we abstracted demographic data, clinical diagnosis, and clozapine dosage,
exposure duration, and the lowest ANC. Two senior CIAC clinicians evaluated all available
data to verify CIAG case status. Most DNA samples were extracted from peripheral venous
blood; a subset of DNA samples were from lymphoblastoid cell lines or oral sources. Most
samples were subjected to standard quality control procedures (DNA quantification,
electrophoresis to assess degradation, and genotyping a “fingerprint” of 25 common SNPs
using a Sequenom iPLEX panel). Genotype data confirmed that all subjects were
independent and of European ancestry (see below).
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A combination of clozapine-treated and untreated controls was used to increase statistical
power. Clozapine-treated controls had received clozapine for over one year with no
documented ANC < 1,500/mm3 and no medical condition with an increased risk of
agranulocytosis. Ascertainment of clozapine-treated controls was performed in the same
manner as for the cases. Untreated controls were broadly consented population controls
ascertained in unrelated disease and cohort studies. Allele frequency data from the NHLBI
Exome Sequencing Project (ESP) were also used.
Generation of Genome-wide Array Data

Author Manuscript
Author Manuscript

385 samples from CIAC (135 cases and 249 treated controls) were genotyped on the
Illumina OmniExpress array at Duke University. We supplemented the CIAC data with 839
untreated population controls from the United Kingdom Blood Service cohort who were
genotyped on the Illumina OmniExpress platform at the Broad Institute. In addition, 26 case
samples from the International Serious Adverse Events Consortium (iSAEC, http://
www.saeconsortium.org) were genotyped at Duke University. These data were merged with
108 untreated population controls from the NIMH repository genotyped on Illumina arrays
at the University of Michigan. Genotype calls were generated using Illumina’s
GenomeStudio software. All samples had a call rate > 98% and an inbreeding coefficient
between −0.2 and 0.2. SNPs were included if the call rate was > 98%, were in HardyWeinberg equilibrium (Pcontrol > 1×10−6, Pcase > 1×10−10), and the call rate difference
between cases and controls was < 0.02. Samples were unrelated and of European ancestry
via multidimensional scaling24. We used SHAPEIT25, 26 and IMPUTE227 to impute
genotypes for all SNPs using 1000 Genomes Project data as a reference panel. The
imputation reference set was 2,186 phased haplotypes from the 1000 Genomes Project
(August 2012, 30,069,288 variants, release “v3.macGT1”, http://mathgen.stats.ox.ac.uk/
impute/data_download_1000G_phase1_integrated.html). Imputation was done for each
platform separately (OmniExpress, I550K) to avoid platform-based batch effects in
imputation.
Generation of Whole-Exome Sequencing Data

Author Manuscript

We sequenced 41 CIAC cases and 26 iSAEC cases at Duke University. Exome sequence
from CIAC cases was captured using Agilent SureSelect 50MB kits (Santa Clara, CA) and
sequenced using Illumina HiSeq 2000 (San Diego, CA) for paired-end 100 bp reads. The
iSAEC samples were sequenced several years earlier using Agilent SureSelect kits (Santa
Clara, CA) and Illumina GAII for paired-end reads (San Diego, CA). For controls, we used
data from 376 phenotypically normal controls who had been exome sequenced at the Broad
Institute28. All raw FASTQ data were processed using the same Picard pipeline29, 30 and
genotype calls were generated for all data jointly using the GATK Unified Genotyper tool31
in order to avoid batch effects.
Individual genotype calls were filtered by requiring read depth ≥ 10, genotype quality score
≥ 30, and meeting specified allelic balance criteria (based on genotype: for 0/0 0–0.3; for 0/1
0.3–0.7; and for 1/1 0.7–1.0). All variants were required to have a GATK PASS rating, to be
biallelic, not to have a significant difference in call rate between cohorts (P > 0.01)
(eliminates biases due to a variant being sequenced in one cohort but not another), and not to
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be an insertion/deletion variant. Samples were required to have a call rate > 95%, < 600
singleton calls, and a Ti:Tv ratio between 3.1 and 3.4. The first ten principal components
were computed using PLINK with 14,466 independent variants with a MAF > 5% and not
located in the MHC region.
Generation of Exome Array Data

Author Manuscript

We genotyped deleterious exonic variation and a comprehensive set of MHC tag SNPs using
the Illumina HumanExome array (v1.0, http://genome.sph.umich.edu/wiki/
Exome_Chip_Design). Initial genotyping was conducted at Duke University and genotype
calls were made using GenomeStudio (v2010.3, genotyping module v1.8.4) using the default
Illumina cluster file. Samples were removed for missingness > 1% (based on common SNPs
with MAF > 5%) or genome-wide heterozygosity outside the range of 0.1–1.2% (based on
rarer SNPs with MAF < 5%) using the original GenomeStudio calls. Cases that failed
quality control (N=23) were re-genotyped at the Broad Institute on the Illumina
HumanExome array (v1.1); genotype calling and quality control were the same as for the
Duke data except that a custom cluster file and a missingness threshold > 2% were used. We
then used zCall to recover rare genotypes.32 After removing poorly performing samples,
individual SNPs from the Duke data were included if they had a call rate > 97% from the
original GenomeStudio calls, a HWE p-value > 1×10−5 and a call rate > 99.5% calculated
from the zCalls. For the Broad data, more lenient call rate thresholds were used due to the
small number of samples (GenomeStudio calls > 75%, zCalls > 95%).

Author Manuscript

The passing exome array data were merged with population controls of European ancestry
broadly consented for biomedical studies. These controls included samples from the NIMH
repository (n=1,037)33, POPRES (n=703)21, the Prospective Registry in IBD Study
(n=254)34, the 1000 Genomes Project (n=449)35, and controls ascertained for an age-related
macular degeneration study (n=704)36. Quality control for the shared controls was similar to
the steps for the CIAC data, except that a call rate of 99% was used36. The final dataset
included only SNPs passing quality control in all cohorts. We removed one member of
putative relative pairs (π̂ > 0.2) and used EIGENSOFT37 to calculate the first 10 principal
components based on 16,621 SNPs (MAF > 5%, excluding the extended MHC region
(chr6:25–35 mb), and following LD pruning). 213/3366 controls were ascertained for not
having CIAG.
HLA Allele Imputation

Author Manuscript

HLA classical alleles and amino acids were imputed using BEAGLE38 for exome array data
or IMPUTE227 for genome array data with a reference set of 5225 samples from the Type 1
Diabetes Genetics Consortium15. The imputation accuracy using this reference panel is
extremely high. For example, the SNP2HLA authors found the accuracy of HLA-B*38:01
was 99.8%, HLA-B*39:01 was 99.8%, and HLA-B*39:06 was 99.9% using the same set of
MHC tag SNPs present on the Illumina HumanExome array compared to direct genotyping
of these variants15. We also confirmed the accuracy of imputation of HLA-DQB1*05:02 by
SNP2HLA using existing data for 19 samples that had PCR-based sequencing of HLADQB1 6672G>C, which is in strong LD with HLA-DQB1*05:027: 37/38 imputed HLADQB1*05:02 calls were concordant with the PCR-based sequencing results.
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Principal components (PCs) were calculated using EigenSoft with the merged OmniExpress
and I550K/I610K imputed datasets. SNPs used to calculate the principal components were
independent (LD pruned) and did not include the MHC (chr6:25–35 Mb). We tested the first
20 principal components for phenotype association (using logistic regression) and evaluated
their impact on the genome-wide test statistics using λ, a measure of how much the observed
distribution of P-values deviates from the expected distribution of P-values. Five principal
components (1–4 and 12) were included in all association analyses. The first four PCs were
selected because it is standard practice to include the first four PCs in analyses to account
for ancestry and, of PC5–PC20, PC12 was the only PC associated with case-control status
(P<0.05). We performed a mega-analysis between the OmniExpress data and the I550K/
I610K imputed dosage data using PLINK with principal components (described above) as
covariates for logistic regression. SNPs with an INFO score ≥ 0.6 (metric of imputation
quality for a SNP) and MAF ≥ 1% in controls were considered passing. We did not observe
any batch effects due to multiple platforms or confounding due to population ancestry as
indicated by a value of λ = 1.047 and no false positive results (Supplementary Fig. 2).
Immune-mediated SNP Enrichment

Author Manuscript

To determine whether our GWAS results show any indication of signal in loci known to be
associated with autoimmune diseases, we randomly drew P-values from the GWAS results
above to create an expected null distribution. In order to make this comparison more
representative in terms of power per SNP, random draws were only taken from the subset of
variants with MAF > 0.05 and INFO > 0.8 (6,752,294 SNPs). We drew 100 sets of 838
SNPs and compared the distribution of p-values to those observed in a curated list of 838
associations to immune-mediated and autoimmune disease curated from the NHGRI GWAS
catalog. The comparison demonstrated that CIAG association to known immune-mediated
SNPs was not distinguishable from random draws of SNPs.
Exome-wide rare variant association study

Author Manuscript

Because we had data from different platforms for rare exonic variants (exome sequencing,
array, and allele counts from the Exome Sequencing Project11, ESP, available at http://
evs.gs.washington.edu/EVS), we used the following procedure to combine allele counts. If a
variant was assayed on multiple platforms, we ensured the MAFs between the controls did
not differ (P > 0.001). If the MAFs in controls were not compatible, we removed data in the
following order: ESP, exome array, and exome sequencing. For each variant, we added
allele counts for each technology in both cases and controls and used Fisher’s exact test on
the combined sample to test for significance.
Variants were functionally annotated using the Variant Effect Predictor tool from
Ensembl39. We then divided the annotations into three categories. The most restrictive
grouping included all nonsense and splice-region variants. The intermediate grouping
included all nonsense, splice-region, and missense variants annotated as probably damaging
by PolyPhen-240. The least restrictive grouping included all nonsense, splice-region,
missense, and untranslated region variants. To test for an excess burden of rare and
functional variants, we used Fisher’s exact test where the variable of interest is the number
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MHC Association Analysis
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of carriers of a functional variant. We used the number of carriers of a functional variant
instead of the total minor allele count as the testing variable to account for LD between
variants.

Model Comparison

We used imputed HLA classical alleles from all samples that were genotyped on the exome
array. For the remaining samples that were not genotyped on the exome array, we imputed
HLA classical alleles from either OmniExpress or I500K. Principal components were
calculated from 6000 independent markers that were present on all three platforms to obtain
one consistent set of principal components for all samples using PLINK (Supplementary
Fig. 5). We merged the imputed dosage data from all three platforms to do a mega-analysis
and used logistic regression to calculate association test statistics for each imputed allele
using the first 10 principal components as covariates in PLINK to account for any
confounding due to population structure. For conditional analyses, we used the dosage of the
conditioning marker as an additional covariate in the analysis.

We used R to compute the log-likelihood of a logistic regression model consisting of either
the top two BTNL2 missense variants or HLA-DQB1 126Q and HLA-B 158T dosages with
the first ten principal components as covariates in 144 cases and 3,355 controls. We also
explored whether adding one or both BTNL2 variants improved the model consisting of
HLA-DQB1 126Q and HLA-B 158T.
Linkage Disequilibrium Calculations

Author Manuscript

We used PLINK to calculate the R2 between each pair of variants in both cases and controls
who had BTNL2 and HLA imputation data (n=146 cases and 3,364 controls). Haploview41
was used to plot the LD between the top BTNL2 variants, HLA-B 158T, HLA-DQB1 126Q
alleles, and the top HLA-DRB1 alleles (*04:02 and *16:01).
Wilcoxon-Rank Sum Tests

Author Manuscript

We used a Wilcoxon-Rank Sum test in R to determine whether the ANC distribution
between carriers and non-carriers of HLA risk alleles was different in cases who had a
lowest recorded ANC ≤ 1000 (n=149). To correct for covariates, we used the residuals of the
regression between ANC and the principal components and cohort indicator as the
quantitative variable for the Wilcoxon-rank sum test (Supplementary Fig. 8). For samples
with dosage, treatment duration, and minimum ANC available (n = 92), we calculated the
correlation between these variables. ANC is moderately correlated with treatment duration
(R2 = 0.165) and weakly correlated with clozapine dosage (R2 = 0.035). Treatment duration
is moderately correlated with dosage (R2 = 0.229). Carrier status was determined using the
best guess genotype for the HLA-B 158T and HLA-DQB1 126Q alleles.
Copy Number Variation Analysis
To generate CNV genotypes, we applied PennCNV to the Illumina OmniExpress data. We
removed any samples that had a log R ratio standard deviation > 0.3 or that were above the
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95th percentile for the number of CNV calls leaving 134 cases and 242 controls. CNVs
included for analysis were required to have > 10 SNP probes, > 20 kb in length, < 50%
overlap with large genome gaps, and with MAF < 1% in controls. We used PLINK to test
for CIAG association using the “--cnv-test-2sided” command with significance determined
using 100,000 permutations. The family-wise corrected P-values were examined. No rare
CNV was significantly associated with CIAG (data not shown).
Molecular Docking

Author Manuscript

We used the Maestro 2012 software suite (Schrödinger, http://www.schrodinger.com) to
build a homology model of HLA-B39 using the protein structures of HLA-B*08 (Protein
Data Bank, PDB, http://www.wwpdb.org, code = 3SPV, resolution 1.30Å) and HLA-B*41
(PDB code = 3LN4, resolution 1.30 Å) as templates. We also used a multiple sequence
alignment encompassing HLA-B*08, B41, and B38. Clozapine was docked into the antigenpresenting site of the predicted structure of HLA-B39 using the Glide program in extraprecision docking mode (Glide XP). Ionizable groups were first converted to their most
probable charged forms at pH 7.4 using the LIGPREP software within Maestro. The binding
region was defined by a 10Å × 10Å × 10Å box centered on the B39 pocket. A scaling factor
of 0.8 was applied to the van der Waals radii. Default settings were used for all the
remaining parameters. The docking poses were energy-minimized with Macromodel in the
OPLS2005 force field with flexible ligand and rigid receptor. The refined poses were reranked on the basis of the calculated interaction energy. The lowest-energy pose was
selected and rescored in the active site using GlideScore XP. Clozapine was also docked in
the antigen-presenting sites of HLA-B*57:01 (PDB code = 3VRI), HLA-B*35:08 (PDB code
= 3BWA), and the binding pockets of other HLA-A and HLA-B proteins.
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Figure 1. Study Design

Our study design consisted of looking for genetic associations with CIAG across the minor
allele frequency spectrum. (A) First, we recruited CIAG cases (red circle) and both treated
and untreated controls (blue circles). Next, we used multiple technologies to genotype
variants including genotyping arrays for both common and rare variants, whole-exome
sequencing, imputation of classical HLA 4-digit alleles and amino acids in the major
histocompatibility complex, and copy number variants. Lastly, we performed association
tests for each class of variants. Results that exceeded the multiple testing threshold are
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colored in yellow. References to figures and tables are listed in blue italics. (B) We used
multiple technologies to genotype variants including whole-exome sequencing (green),
exome array (pink), OmniExpress (blue) and Illumina 550K genome-wide arrays (orange).
In addition, we used allele counts from the Exome Sequencing Project as extra control
chromosomes (purple). As demonstrated by the Venn diagrams, the majority of cases
(n=163) and treated controls (n=250) were genotyped on more than one platform.
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Figure 2. GWAS Manhattan Plot
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We performed a genome-wide association study for 161 cases and 1196 controls. We did not
find any loci that exceeded the threshold for genome-wide significance of 5×10−8 (red line).
The most significant SNP is rs41549217, in an intron of HLA-B (P=2.07×10−7, logistic
regression).
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Figure 3. Gene-Burden Test Results
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We evaluated whether cases were more likely to carry rare functional variants in a gene
compared to controls using sequencing data from 67 cases and 376 controls. Variants were
annotated using the Variant Effect Predictor tool and divided into three sets of severity. The
most severe category consists of loss-of-function (LOF) variants annotated as being
nonsense and splice site (green). The intermediate category included all LOF variants as
well as missense variants annotated as probably damaging by PolyPhen-2 (magenta). The
least severe category consisted of all LOF, missense, and untranslated region (UTR) variants
(blue). We had varying minor allele frequency (MAF) cutoffs with the most restrictive being
0–1% MAF and the most inclusive being 0–5%. For each MAF and variant set, we assessed
whether any genes deviated from expectation as demonstrated by the diagonal line. The only
gene that showed enrichment was BTNL2 (P=7.0×10−8, Fisher’s Exact Test).
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Figure 4. Manhattan Plot of the MHC Region from HLA Imputation

This figure shows the association results of CIAG to imputed HLA classical alleles, amino
acids, and SNPs for 161 cases and 4300 controls. (A) The top signal is from a single amino
acid in HLA-DQB1 (126Q) (P=4.7×10−14, OR=0.19, logistic regression). All variants with
an R2 > 0.1 with HLA-DQB1 126Q are colored green. (B) After conditioning on HLA-DQB1
126Q as demonstrated by the green arrow, the top signal is a single amino acid in HLA-B
(158T) (Pcond =1.54×10−8, OR=3.11, logistic regression). All variants with an R2 > 0.1 with
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HLA-B 158T are colored purple. (C) After conditioning on HLA-DQB1 126 Q and HLA-B
158T (purple and green arrows), no genome-wide significant loci remain.
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Figure 5. Absolute Neutrophil Count Stratified by HLA Risk Allele Carrier Status
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(A) For cases in which the lowest recorded absolute neutrophil count (ANC) data were
available, we ordered samples by the ANC and colored the points by their imputed carrier
status of HLA-DQB1 126Q and HLA-B 158T (black=no risk alleles, red=only a carrier of
HLA-DQB1 risk alleles as tagged by 126Q, green=only a carrier of HLA-B 158T,
blue=carrier of both HLA-DQB1 and HLA-B risk alleles). The background colors
demonstrate the clinical definitions for agranulocytosis (red: ANC<500) and severe
granulocytopenia (yellow: 500≤ANC≤1000). (B) The same data are shown as a box plot to
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demonstrate that HLA-B 158T carriers demonstrate a trend towards lower ANC than noncarriers of HLA-B 158T.
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Figure 6. Predicted binding pose of clozapine in the antigen-presenting pocket of HLA-B* 39
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Docking of clozapine into the putative antigen binding pocket of the homology model of
HLA-B39 identified a binding pose (shown in this figure) with the highest predicted binding
affinity. Residues in the protein binding pocket involved in specific interactions with
clozapine are annotated.
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